Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: A retrospective,observational,multicentric study

Abstract

Aims and background:

Erlotinib approval was supported by the positive results of a large multicentric phase III trial (BR.21 study) that included 10% Asiatic patients and the remaining were North-American Caucasian. It is well-known that the efficacy of tyrosine kinase inhibitors is strongly influenced by ethnicity and other genetic factors. It is, therefore, relevant to establish whether the same profile of efficacy is seen in an unselected population and whether the results of BR.21 can be generalized to other patient populations, such as that described here.

Methods:

In this retrospective, observational, multicentric study, we assessed effectiveness and potentially response predictive factors in 222 unselected Italian patients, with stage IIIB/IV non-small-cell lung cancer, with performance status from 0 to 3, who had received at least one line of chemotherapy, treated with the standard dose of erlotinib (150 mg once daily) until disease progression or unacceptable toxicity.

Results:

The disease control rate was 60.9% (135 patients). Median progression-free survival and overall survival times were 3.1 months and 7.97 months, respectively. The characteristics of non-smoker, female gender, performance status 0 or 1 were associated with a significantly better prognosis in terms of disease control rate and were also predictive of longer overall survival and progression-free survival. The 1-year survival rate was 38.79%. Even though Italian patients baseline characteristics were strongly different to those reported in pivotal BR.21 trial in terms of age, performance status, line treatment and ethnic group, our study confirms the favorable effectiveness profile in real clinical practice of erlotinib according to results from the pivotal study BR.21.

Conclusions:

Today, we know that epidermal growth factor receptor (EGFR) status assessment is mandatory before starting first-line therapy and that the presence of only certain clinical characteristics initially associated with sensitivity to EGFR-tyrosine kinase inhibitors, as reported in this study, is not sufficient in selecting patients candidates to such treatments.

Keywords

Erlotinib effectiveness response predictive factors

Get full access to this article

View all access options for this article.

References

Gompelmann

Eberhardt

Herth

. Advanced malignant lung disease: what the specialist can offer. Respiration 2011; 82: 111–123.

Reck

van Zandwijk

Gridelli

. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010; 5: 1616–1622.

Vray

Hamelin

Jaillon

. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. Therapie 2005; 60: 339–344.

Shepherd

Dancey

Ramlau

. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.

Fossella

DeVore

Kerr

. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum- containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354–2362.

Hanna

Shepherd

Fossella

. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–1597.

Dempke

Suto

Reck

. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67: 257–274.

Shepherd

Rodrigues Pereira

Ciuleanu

. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123–132.

Italian Medicines Agency (AIFA). Program of Innovative Drugs Monitoring, http://antineoplastici.agenziafarmaco.it/ (2006, accessed January 2007).

10.

Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgenol 2010; 195: W221–W228.

11.

Faehling

Eckert

Kuom

. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 2010; 78: 249–258.

12.

Goodin

. Erlotinib: optimizing therapy with predictors of response?. Clin Cancer Res 2006; 12: 2961–2963.

13.

Hsieh

Lim

Kuo

. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005; 128: 317–321.

14.

Rosell

Moran

Queralt

. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958–967.

15.

Rossell

Carcereny

Gervais

. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutations-positive NSCLC (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239–246.

16.

Zhou

Chen

. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, ope-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.

17.

Mitsudomi

Morita

Yatabe

. Gefitinib versus cisplatin plus docetaxel in patients with NSCLS harbouring mutations of the EGFR (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–128.

18.

Maemondo

Inoue

Kobayashi

. Gefitinib or chemotherapy for NSCLC with mutated EGFR. N Engl J Med 2010; 362: 2380–2388.

19.

Mok

. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 362: 947–957.

20.

Landi

Capuzzo

. Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make difference?. J Thorac Dis 2012; 4(2): 226–228.

21.

Capuzzo

Ciuleanu

Stelmakh

. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11(6): 512–529.

22.

Vergnenègre

Ray

Chouaid

. Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable NSCLC. Clinicoecon Outcomes Res 2012; 4: 31–37.